TILRAY BRANDS INC (TLRY)
US88688T1007 - Common Stock
Taking everything into account, TLRY scores 3 out of 10 in our fundamental rating. TLRY was compared to 198 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, TLRY is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TLRY had negative earnings in the past year.
TLRY had a negative operating cash flow in the past year.
TLRY had negative earnings in each of the past 5 years.
TLRY had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
TLRY has a Return On Assets of -8.35%. This is in the better half of the industry: TLRY outperforms 74.49% of its industry peers.
TLRY's Return On Equity of -10.48% is fine compared to the rest of the industry. TLRY outperforms 79.59% of its industry peers.
TLRY has a better Return On Invested Capital (1.55%) than 79.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.35% | ||
| ROE | -10.48% | ||
| ROIC | 1.55% |
ROA(3y)-23.71%
ROA(5y)-23.46%
ROE(3y)-42.39%
ROE(5y)-54.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TLRY has a better Operating Margin (10.30%) than 83.67% of its industry peers.
With a Gross Margin value of 28.01%, TLRY perfoms like the industry average, outperforming 52.04% of the companies in the same industry.
TLRY's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.3% | ||
| PM (TTM) | N/A | ||
| GM | 28.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-15.87%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TLRY is destroying value.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
Compared to 5 years ago, TLRY has more shares outstanding
Compared to 1 year ago, TLRY has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.40, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
TLRY has a Altman-Z score (0.40) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.11 indicates that TLRY is not too dependend on debt financing.
TLRY's Debt to Equity ratio of 0.11 is in line compared to the rest of the industry. TLRY outperforms 48.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.4 |
ROIC/WACC0.2
WACC7.74%
2.3 Liquidity
TLRY has a Current Ratio of 1.92. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.92, TLRY is doing worse than 66.84% of the companies in the same industry.
TLRY has a Quick Ratio of 1.18. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
TLRY has a Quick ratio of 1.18. This is in the lower half of the industry: TLRY underperforms 76.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 91.78% over the past year.
Looking at the last year, TLRY shows a very strong growth in Revenue. The Revenue has grown by 24.66%.
The Revenue has been growing by 98.21% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)91.78%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q100%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y55.43%
Revenue growth 5Y98.21%
Revenue growth Q2Q29.35%
3.2 Future
The Earnings Per Share is expected to grow by 15.33% on average over the next years. This is quite good.
TLRY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.94% yearly.
EPS Next Y90.13%
EPS Next 2Y39.84%
EPS Next 3Y25.27%
EPS Next 5Y15.33%
Revenue Next Year33.01%
Revenue Next 2Y21.64%
Revenue Next 3Y18.07%
Revenue Next 5Y17.94%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TLRY. In the last year negative earnings were reported.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TLRY indicates a rather cheap valuation: TLRY is cheaper than 93.37% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.47 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TLRY's earnings are expected to grow with 25.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.84%
EPS Next 3Y25.27%
5. Dividend
5.1 Amount
TLRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TILRAY BRANDS INC
NASDAQ:TLRY (4/16/2024, 1:38:07 PM)
1.86
+0.08 (+4.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.42B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.35% | ||
| ROE | -10.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 10.3% | ||
| PM (TTM) | N/A | ||
| GM | 28.01% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)91.78%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y90.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)24.66%
Revenue growth 3Y55.43%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y